2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1716 Fusion context shapes genomic architecture and defines the biologic and prognostic significance of cooperating variants in core-binding factor AML in children and young adults

Maya Rose Ball-Burack, MD, Jack H. Peplinski, MSc2, Rhonda E. Ries, MA3, Katherine Tarlock I, MD4, Danielle Kirkey5, Soheil Meshinchi, MD, PhD6
1 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
2 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
5 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
6 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States

Core-binding factor (CBF) AML comprises two fusion-driven leukemias initiated by RUNX1::RUNX1T1 (t(8;21)) and CBFB::MYH11 (inv(16)). Both fusions can arise in utero, yet they show different age distributions: inv(16) AML is more frequent <3 years of age compared to t(8;21) AML (18% vs 2%), while t(8;21) is more common after age 5, suggesting distinct developmental trajectories after fusion acquisition. Here we define fusion-specific genomic alterations, variant molecular pathways, and their distinct prognostic effects in CBF AML.

Molecular characterization was performed on children and young adults with t(8;21) or inv(16) AML enrolled on Children’s Oncology Group trials. Of 657 evaluable patients with CBF AML, 370 had t(8;21) and 287 had inv(16). Cooperating alterations were grouped into pathways: RTK/RAS signaling, chromatin regulation, transcription factor regulation, cohesin biology, DNA methylation, RNA splicing and tumor-suppressor.

Despite disrupting the same transcriptional complex, the two subtypes demonstrated distinct pathway specific alterations when evaluated with Fisher’s exact test. t(8;21) AML was enriched in alterations involving chromatin regulation (34% vs 10%; Padj < 0.0001), notably ASXL1/2 and KDM6A; transcription factor regulation (17% vs 7%; Padj < 0.0001), including SPI1, GATA2, IKZF1, NCOR1 and MGA; DNA methylation (12% vs 2%; Padj < 0.0001), including IDH1/2 and TET2; RAD21, a cohesin complex subunit (6% vs 1%,) and RNA splicing (6% vs 0%; Padj = 0.0026). Cytogenetic abnormalities were more frequent in t(8;21) AML (63% vs 28%; Padj < 0.0001) particularly del(9q), X and Y. Conversely, inv(16) AML had preferential acquisition of RTK alterations, including NRAS (53% vs 28% in t(8;21); Padj < 0.0001), and recurrent KRAS, FLT3, KIT exon 17, PTPN11, JAK3 and PTEN alterations.

To identify fusion-specific prognostic factors, we ran Cox regression analyses of recurrent alterations and predefined biologic pathways. 5-year event-free survival (EFS) were estimated by Kaplan-Meier methods. Adverse EFS in t(8;21) AML was associated with SPI1, IDH1/2, trisomy 4, ASXL1, CCND2 and the DNA methylation pathway, while adverse EFS in inv(16) AML was dominated by FLT3-ITD, CSF3R, KIT exon 17 and cohesin alterations.

Cohesin alterations provided clear evidence of fusion-dependent clinical significance—they were more frequent in t(8;21) AML (12% vs 6%; P=0.12) and associated with superior EFS (83% vs 64% without cohesin alterations; P=0.02), driven predominantly by RAD21. Strikingly, cohesin alterations in inv(16) AML identified a subgroup with markedly inferior EFS (15% vs 62% without cohesin alterations; P < 0.0001).

A fusion-dependent pattern was also observed for RTK alterations. In inv(16) AML, FLT3-ITD had EFS of 7% vs. 58% in patients without FLT3-ITD (P < 0.0001), whereas FLT3-ITD was not associated with worse outcomes in t(8;21) AML (EFS 50% vs 64%; P=0.3316). KIT exon 17 alterations were also associated with inferior EFS (32% vs 65%; P=0.0002) in inv(16) AML, but not t(8;21) AML (60.6% vs 68.1%; P=0.3377). Conversely, alterations of methylation and transcriptional regulation—particularly SPI1, IDH1/2, ASXL1 and CCND2—identified adverse subsets in t(8;21) AML but were uncommon or non-prognostic in inv(16) AML.

Composite groups constructed using alterations associated with fusion-specific inferior EFS identified high-risk subsets. In t(8;21) AML, grouped patients with subtype-specific adverse alterations (DNA methylation, SPI1, IDH1/2, CCND2, ASXL1, trisomy 4) had EFS of 44% vs 69% (P<0.0001). In inv(16) AML, grouped patients with subtype-specific adverse alterations (cohesin family, CSF3R, KIT Exon 17, FLT3-ITD) had EFS of 27% vs 65% (P<0.0001).

Historically grouped and classified as favorable-risk, t(8;21) and inv(16) AML represent distinct leukemias with characteristic pathway-level genomic architectures that modify biology and prognosis. t(8;21) AML is enriched for alterations in chromatin, epigenetic, and cohesin regulation, whereas inv(16) AML is characterized predominantly by RTK/RAS signaling alterations. This large cohort reveals divergent clinical implications of cohesin alterations, FLT3-ITD and KIT exon 17, showing that CBF fusion alone is insufficient for risk prognostication. These findings establish a framework for fusion-specific molecular risk stratification and identify biologically defined pathways for precision therapeutic investigation in children and young adults with CBF AML.

Maya Rose Ball-Burack, MD: No relevant conflicts of interest to declare.